Smith Asset Management Group LP now owns 11,990 shares of the company's stock valued at $227,000 after buying an additional 230 shares during the period. Essex Investment Management Co. Atria Investments LLC acquired a new position in shares of Amphastar Pharmaceuticals during the third quarter valued at approximately $190,000. LLC now owns 105,239 shares of the company's stock worth $1,696,000 after buying an additional 73,922 shares in the last quarter. LPL Financial LLC raised its position in Merrimack Pharmaceuticals by 6.1% in the third quarter. Finally, Bank of New York Mellon Corp boosted its stake in Amphastar Pharmaceuticals by 49.0% in the second quarter. Needham & Company LLC boosted their price target on Amphastar Pharmaceuticals from $20.00 to $22.00 and gave the stock a buy rating in a report on Tuesday, August 9th. Merrimack Pharmaceuticals has a one year low of $4.04 and a one year high of $9.02. The company has a market cap of $925.43 million, a PE ratio of 66.59 and a beta of 1.86. The firm has a 50-day moving average price of $5.52 and a 200-day moving average price of $5.42. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.27) by $0.04. The company had revenue of $64.20 million for the quarter, compared to analyst estimates of $65.12 million. Amphastar Pharmaceuticals had a net margin of 7.75% and a return on equity of 6.79%.
Merrimack Pharmaceuticals (NASDAQ:MACK) last released its quarterly earnings results on Wednesday, November 9th. During the same quarter previous year, the firm posted ($0.38) EPS.
Immune Pharmaceuticals Inc had its "outperform" rating reiterated by analysts at FBR Capital Markets.
TRADEMARK VIOLATION NOTICE: This article was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another publication, it was stolen and republished in violation of US & global copyright & trademark laws.
03/09/2015 - AVEO Pharmaceuticals, Inc. was upgraded to "sector perform" by analysts at RBC Capital.
AMPH has been the subject of a number of recent analyst reports.
Recently analysts working for various investment brokerages have changed their ratings and price targets on shares of Immune Pharmaceuticals Inc (IMNP).
The share price of the company (IMNP) was down -0.27%, with a high of 0.18 during the day and the volume of Immune Pharmaceuticals Inc shares traded was 2204451. (NASDAQ:AMPH) from a buy rating to a hold rating in a research report report published on Monday morning. Amphastar Pharmaceuticals now has a consensus rating of Buy and an average target price of $20.17.
In other news, EVP Diane G. Gerst sold 24,046 shares of the business's stock in a transaction that occurred on Friday, August 19th. The shares were sold at an average price of $20.51, for a total transaction of $60,299.40. Following the transaction, the executive vice president now owns 39,031 shares of the company's stock, valued at approximately $752,517.68. Also, Director Howard Lee sold 37,994 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $19.28, for a total transaction of $463,606.88. Following the transaction, the director now owns 134,527 shares in the company, valued at approximately $2,777,982.55. The disclosure for this sale can be found here.
According to Zacks, "Amphastar Pharmaceuticals, Inc.is a specialty pharmaceutical company". The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.